These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 34931528)

  • 1. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.
    Ziemssen T; Kurzeja A; Muresan B; Haas JS; Alexander J; Driessen MT
    Neurodegener Dis Manag; 2022 Apr; 12(2):93-107. PubMed ID: 34931528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework.
    Brnabic AJM; Curtis SE; Johnston JA; Lo A; Zagar AJ; Lipkovich I; Kadziola Z; Murray MH; Ryan T
    PLoS One; 2024; 19(3):e0300708. PubMed ID: 38517926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
    Zagmutt FJ; Carroll CA
    Int J Neurosci; 2015; 125(11):798-807. PubMed ID: 25387069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
    Earla JR; Li J; Hutton GJ; Bentley JP; Aparasu RR
    Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
    Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
    Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
    Zanghì A; Avolio C; Amato MP; Filippi M; Trojano M; Patti F; Amico E;
    Mult Scler Relat Disord; 2022 Feb; 58():103489. PubMed ID: 35032879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
    Bsteh G; Aicher ML; Walde JF; Krajnc N; Haider L; Traxler G; Gradl C; Salmen A; Riedl K; Poskaite P; Leyendecker P; Altmann P; Auer M; Berek K; Di Pauli F; Kornek B; Leutmezer F; Rommer PS; Zulehner G; Zrzavy T; Deisenhammer F; Chan A; Berger T; Hoepner R; Hammer H; Hegen H
    Neurology; 2024 Sep; 103(6):e209752. PubMed ID: 39197111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
    Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP
    Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
    Jivraj F; Kang S; Reedie S; Kapadia S; Strzok S; Elliott E; Cano S; Rock M
    Adv Ther; 2022 Nov; 39(11):5072-5086. PubMed ID: 36053450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
    Hillert J; Tsai JA; Nouhi M; Glaser A; Spelman T
    Mult Scler; 2022 Feb; 28(2):237-246. PubMed ID: 34080926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.